PDF Document

Source URL: www.spl.ch

AMS INTERLINE NETWORK SCHEDULE S15 (29 March 2015 to 24 OctoberVia SPL FLT.# NCA Interline Network LTL Service Connecting to:

Source URL: www.nca.aero

VivaGel® condom approved for sale with launch imminent Melbourne, Australia; 2 October 2014: Starpharma (ASX:SPL, OTCQX:SPHRY) today announced the inclusion of the VivaGel® condom in the Australian Register of Therapeu

Source URL: www.starpharma.com

• Condoms
• Antiseptics
• Microbicides
• Microbicides for sexually transmitted diseases
• LifeStyles Condoms
• Female condom
• Ansell
• Australian Securities Exchange
• Dendrimer
• Chemistry
• Medicine
• Biology

Quarterly Cashflow Report Melbourne, Australia; 31 October 2014: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 SeptemberThe

Source URL: www.starpharma.com

• Cash flow
• Financial statements
• Cash flow statement
• Microbicides for sexually transmitted diseases
• Condom
• Operating cash flow
• Working capital
• Net asset value
• Equity
• Finance
• Accountancy
• Business

Quarterly Cashflow Report Melbourne, Australia; 28 January 2015: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 DecemberThe c

Source URL: www.starpharma.com

• Cash flow
• Generally Accepted Accounting Principles
• Financial statements
• Cash flow statement
• Financial services
• Funds
• Microbicides for sexually transmitted diseases
• Docetaxel
• Operating cash flow
• Finance
• Accountancy
• Business

VivaGel® condom now available in Australian stores Melbourne, Australia; 29 October 2014: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) is pleased to announce that the Company has been notified by its commercial part

Source URL: www.starpharma.com

• Condoms
• Antiseptics
• Microbicides
• Microbicides for sexually transmitted diseases
• HIV/AIDS
• Condom
• LifeStyles Condoms
• Female condom
• Dendrimer
• Chemistry
• Medicine
• Biology

Starpharma receives $4.7M R&D tax incentive Melbourne, Australia; 11 March 2014: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has received the anticipated $4.7M of R&D tax incentive relating to FY13 expenditure

Source URL: www.starpharma.com

• Alkaloids
• Benzoates
• Carbamates
• Docetaxel
• Microbicides for sexually transmitted diseases
• Dendrimer
• Prostate cancer
• Clinical trial
• Australian Securities Exchange
• Chemistry
• Medicine
• Health

Healthcare & Biotech Update - Backing De-risked Biotech Advantage to gold standard, Believable managers, Cash Flow January 2015 Ranking of covered companies: Starpharma (SPL) - Buy Medical Developments (MVP) - Buy

Source URL: www.starpharma.com

• Dendrimer
• Financial markets
• Antiseptics
• Microbicides
• Microbicides for sexually transmitted diseases
• Short
• Repurchase agreement
• Finance
• Microbiology
• Financial economics

Starpharma commences Dendrimer-Docetaxel clinical trial Melbourne, Australia; 23 January 2014: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it has received the necessary approvals to commence a phase 1 human

Source URL: www.starpharma.com

• Benzoates
• Carbamates
• Docetaxel
• Cancer treatments
• Dendrimer
• Prostate cancer
• Microbicides for sexually transmitted diseases
• Chemotherapy
• Chemistry
• Medicine
• Alkaloids

Starpharma Interim Report and Half-year Financial Results Melbourne, Australia; 16 February 2015: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today released its interim report and financial results for the half-year

Source URL: www.starpharma.com

• Sexually transmitted diseases and infections
• Antiseptics
• Microbicides
• Microbicides for sexually transmitted diseases
• Alkaloids
• Benzoates
• Docetaxel
• Condom
• Clinical trial
• Medicine
• Chemistry
• Health